{"product_id":"nmtc-bcg-matrix","title":"(NMTC) NeuroOne Medical Technologies Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis NeuroOne Medical Technologies Corporation BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVO sEEG lead, FDA-cleared\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEVO sEEG lead is NeuroOne Medical Technologies Corporation’s clearest commercial product: it already has FDA clearance and fits a repeat-use epilepsy localization workflow. Stereoelectroencephalography (sEEG) is a niche but growing specialty use case, with roughly 30% to 40% of drug-resistant epilepsy patients needing invasive evaluation before surgery. That makes it the strongest Star candidate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEVO cortical strip lead, FDA-cleared\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe FDA-cleared EVO cortical strip lead extends NeuroOne Medical Technologies Corporation’s thin-film platform into cortical monitoring and mapping, so it fits the same neurosurgical workflow. It targets the same customer base as NeuroOne’s other electrodes, which supports cross-selling and lowers sales friction. If adoption widens in this niche, it can build share in a growing segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThin-film intracranial EEG platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s thin-film intracranial EEG platform is the core of its approved leads and the best-fit Star in the BCG matrix. It supports sEEG and cEEG use cases, which sit in growing neurodiagnostic demand as epilepsy and ICU monitoring needs rise. A multi-product cleared platform gives the Company the strongest scale and cross-sell base in its lineup.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEpilepsy surgery workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s cleared tools fit the epilepsy surgery workflow at two key points: presurgical localization and intraoperative use. About 50 million people live with epilepsy worldwide, and roughly 30% remain drug-resistant, so epilepsy centers keep shifting toward more precise monitoring and minimally invasive care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocalization drives device demand.\u003c\/li\u003e\n\u003cli\u003eIntraoperative use adds workflow value.\u003c\/li\u003e\n\u003cli\u003eDrug-resistant cases support growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis makes the workflow a real growth engine for NeuroOne’s cleared devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial neurosurgical consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCommercial neurosurgical consumables look Star-like because NeuroOne Medical Technologies Corporation sells disposable electrodes that can drive repeat orders after a center adopts the platform. The mix shifts value from one-time hardware to recurring use, and that helps reorder economics improve as procedure volume rises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDisposable electrodes support repeat buying\u003c\/li\u003e\n\u003cli\u003eAdoption can lift reorder frequency\u003c\/li\u003e\n\u003cli\u003eRecurring use is the key Star trait\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroOne’s FDA-Cleared Leads Drive Growth in Epilepsy Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s Stars are the FDA-cleared EVO sEEG and cortical strip leads, plus its thin-film intracranial EEG platform, because they fit growing epilepsy localization and monitoring demand. Drug-resistant epilepsy still drives invasive evaluation in about 30% of cases, and disposable electrodes support repeat orders after adoption. That makes these products the clearest growth engine.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEVO sEEG lead\u003c\/td\u003e\n\u003ctd\u003eCleared, repeat-use workflow\u003c\/td\u003e\n\u003ctd\u003e~30% drug-resistant epilepsy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThin-film iEEG platform\u003c\/td\u003e\n\u003ctd\u003eCross-sells multiple leads\u003c\/td\u003e\n\u003ctd\u003eRecurring consumable demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eNeuroOne’s BCG Matrix maps its product lines by growth and share, flagging where to invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG Matrix view for NeuroOne Medical Technologies to pinpoint each product’s role and reduce strategic guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for NeuroOne Medical Technologies Corporation, strengthening credibility and making key assumptions easier to verify and act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo mature cash cow disclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, NeuroOne Medical Technologies Corporation still looked like an early commercial medtech company, not a mature cash generator. Public filings did not show a large, low-growth franchise producing excess cash, and the company was still focused on scaling adoption and managing losses. So this Cash Cows quadrant is effectively empty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepeat sEEG orders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf centers keep reordering NeuroOne Medical Technologies Corporation's cleared sEEG leads, the installed clinical base can drive steady, low-cost sales, which is the cash cow pattern. That matters more than new launches because repeat use in the same centers lowers selling friction and supports margin. But at end-2025 the scale was still small, so it was only cash-cow-like, not a true cash cow yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepeat cortical strip orders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepeat cortical strip orders use the same manufacturing flow and customer base as NeuroOne Medical Technologies Corporation's sEEG line, so each reorder should cost less to serve than a new development sale. That can lift gross cash flow versus R\u0026amp;D-heavy programs, but by end-2025 this line still looked more like an early repeat-sales base than a true cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-capex electrode manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s thin-film electrodes fit the low-capex cash-cow idea because they do not need the heavy plant and systems tied to big hardware builds. That setup can lift gross margin as production scales, but the cash pull is still small because volumes remain limited.\u003c\/p\u003e\n\u003cp\u003eIn the latest reported period, NeuroOne Medical Technologies Corporation posted only modest sales and continued to carry a lean cost base, so the cash benefit from electrode manufacturing is real but not yet large. Every extra unit matters more here because fixed manufacturing investment stays low.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow capital need supports margin gain.\u003c\/li\u003e\n\u003cli\u003eScale helps more than new spending.\u003c\/li\u003e\n\u003cli\u003eCash flow is still volume constrained.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall installed account base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s small installed account base still looks like early adoption, not a true cash cow. The base can support repeat console, lead, and disposable sales, so every new site matters more than the label suggests. End-2025 data still pointed to a build phase, not a mature annuity stream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eRepeat sales are possible, but scale is still thin.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEach account can create support and refill touchpoints.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCash cow status needs broader installed depth.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo Cash Cow Yet: NeuroOne Remains in Build Mode\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation had no true Cash Cows at end-2025. Reorders from sEEG leads, cortical strips, and thin-film electrodes could lower unit selling costs, but sales stayed too small and commercial scale too thin to generate surplus cash. The quadrant remained a build phase, not a mature annuity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eEnd-2025 view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash cow status\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003eModest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled account depth\u003c\/td\u003e\n\u003ctd\u003eThin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital need\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNeuroOne Medical Technologies Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe NeuroOne Medical Technologies Corporation BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages, no watermarks, and no hidden sections—just the complete, professional report. Once purchased, your full file is ready for immediate download and use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo obvious dog disclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNo obvious dog is disclosed in NeuroOne Medical Technologies Corporation’s public portfolio. Its latest filings show a small business still centered on launch-stage and active development assets, not a large legacy line with weak growth and weak share; 2024 revenue was still modest at about $0.9 million. So the classic dog bucket stays limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core legacy concepts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s non-core legacy concepts fit Dogs because older ideas that never reached commercialization can still consume time and cash without building revenue. Public filings did not show a material legacy franchise, and the latest fiscal 2025 reports still point to a small, loss-making base rather than a scaled legacy business. In BCG terms, these projects have low share and weak cash return.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrototype-only device variants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrototype-only device variants can sit in development for 2 to 5 years and still add no share, which fits the dog profile in NeuroOne Medical Technologies Corporation’s small pipeline. Without a 510(k) clearance or a commercial partner, each variant can keep burning cash while revenue stays near zero, so the return on that work is weak. In 2025, that gap between R\u0026amp;D spend and sales is the core dog risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUnproven adjacencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s non-core neuromodulation adjacencies fit \"dogs\" if they fail to gain scale beyond the epilepsy electrode base. The company still leans on one core commercial product, so broader ideas can stay low-share, low-growth until adoption, reimbursement, and repeat sales improve.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak uptake keeps adjacencies in dog territory.\u003c\/li\u003e\n\u003cli\u003eCore business remains the main revenue engine.\u003c\/li\u003e\n\u003cli\u003eScale, not ideas, decides the BCG slot.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStranded R\u0026amp;D spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor NeuroOne Medical Technologies Corporation, stranded R\u0026amp;D spend is the dog risk: in FY2025, development cash can keep draining if a program misses FDA clearance or a licensing deal. Small companies can turn unrecovered R\u0026amp;D into a value trap fast, especially when cash is limited and no product is yet pulling in scale revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWatch FDA milestones, not just spend.\u003c\/li\u003e\n\u003cli\u003eKill weak programs early.\u003c\/li\u003e\n\u003cli\u003ePush for partnerships fast.\u003c\/li\u003e\n\u003cli\u003eProtect cash before value fades.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroOne: Small Revenue, Big Stalled R\u0026amp;D Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation shows little evidence of a true Dogs bucket: 2024 revenue was about $0.9 million, and FY2025 still reflects a small, loss-making base. So the dog risk is mostly non-core or stalled development work, not a large weak legacy franchise.\u003c\/p\u003e\n\u003cp\u003eUncommercialized prototypes and adjacencies can still drain cash if they miss FDA milestones or a partner. In BCG terms, these assets have low share, weak growth, and poor cash return.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog screen\u003c\/th\u003e\n\u003cth\u003eFY2025\/2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eAbout $0.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProfile\u003c\/td\u003e\n\u003ctd\u003eSmall, loss-making\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDog risk\u003c\/td\u003e\n\u003ctd\u003eStalled R\u0026amp;D, no scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOneRF RF ablation generator\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOneRF RF ablation generator is NeuroOne Medical Technologies Corporation’s clearest Question Mark because it targets a large, growing ablation market, with global RF ablation systems still expanding at high single-digit rates through 2025. NeuroOne has worked with RBC Medical Innovations to develop the generator, which supports the product path. Still, commercial share was unproven by end-2025, so upside remained real but not yet validated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual-function monitor-ablate electrode\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s dual-function monitor-ablate electrode is a clear Question Mark: it pairs brain-signal recording with targeted ablation in one tool, so the differentiation is real, but broad adoption still depends on clinical proof, payer coverage, and hospital workflow fit. The upside is large, since one platform can replace multiple steps in epilepsy and neurosurgery care, but the commercial path is still early and capital hungry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpinal cord stimulation program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpinal cord stimulation is a multi-billion-dollar neuromodulation market already led by Abbott, Medtronic, Boston Scientific, and Saluda. NeuroOne Medical Technologies Corporation’s thin-film platform is differentiated, but by end-2025 it still had no meaningful spinal cord stimulation share or material sales, so this unit sits in the invest-or-exit zone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBrain stimulation program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eParkinson’s disease affects about 10 million people worldwide, and brain stimulation also targets essential tremor and dystonia. NeuroOne Medical Technologies Corporation’s program is still early-stage, so current revenue contribution is minimal versus a large, high-value market. In BCG terms, this is a Question Mark: big upside, low share, and high execution risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge neuromodulation demand\u003c\/li\u003e\n\u003cli\u003eLow current market share\u003c\/li\u003e\n\u003cli\u003eEarly development stage\u003c\/li\u003e\n\u003cli\u003eHigh upside, high risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpanded pain and movement-disorder indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation has flagged persistent pain and movement disorders as large targets, and the addressable base is real: chronic pain affects about 1 in 5 adults, while Parkinson's disease tops 10 million people worldwide. But these remain Question Marks because growth still depends on FDA clearance, clinical proof, and sales execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig need, but no clear scale yet.\u003c\/li\u003e\n\u003cli\u003eRegulatory and commercial risk stays high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuroOne’s Biggest Upside Bets Still Need Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeuroOne Medical Technologies Corporation’s question marks are its highest-upside, highest-risk bets: OneRF RF ablation, the dual-function monitor-ablate electrode, spinal cord stimulation, and early brain-stimulation programs. They address large 2025 markets, but by end-2025 share, revenue, and reimbursement proof were still limited, so execution and FDA milestones will decide value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOneRF\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eCommercial proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMonitor-ablate electrode\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eAdoption and coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpinal cord stimulation\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234709152009,"sku":"nmtc-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nmtc-bcg-matrix.webp?v=1785726458","url":"https:\/\/dcfanalyst.com\/products\/nmtc-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}